Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  clofarabine
Find trials that include:  Any drugs shown
Results 1-25 of 26 for your search:
Start Over
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, U10CA098543, NCT01406756
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients with High Risk Malignancies
Phase: Phase II
Type: Treatment
Age: Under 60
Trial IDs: 2008-0363, NCI-2012-01630, NCT00857389
Busulfan and Clofarabine Followed by Donor Stem Cell Transplant in Treating Patients with Acute Leukemia or Lymphoma in Remission or Relapse
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0209, NCI-2012-01270, NCI-2009-01649, NCT00990249
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: not specified
Trial IDs: 2430.00, NCI-2010-02247, 2430.00A, NCT01252667
Clofarabine and Cytarabine in Treating Patients With Relapsed or Refractory Higher-Risk Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0660, NCI-2011-03436, NCT01444742
Clofarabine, Busulfan and Fludarabine Phosphate Followed by Donor Stem Cell Transplant in Treating Young Patients With High Risk Hematological Malignancies or Hematological Disorders
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months to 30 years
Trial IDs: CC #110819, NCI-2012-00800, NCT01596699
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Clofarabine and Melphalan before Donor Stem Cell Transplant in Treating Patients with Myelodysplasia or Acute Leukemia in Remission
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13130, NCI-2013-01193, 107819, NCT01885689
Sorafenib Tosylate, Cytarabine, and Clofarabine in Treating Patients with Refractory or Relapsed Hematologic Malignancies
Phase: Phase I
Type: Treatment
Age: 31 and under
Trial IDs: RELHEM, NCI-2011-01252, NCT00908167
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: BECHEM, NCI-2013-01148, TEVA ISS, NCT01900509
Fludarabine Phosphate, Clofarabine, and Busulfan with Vorinostat in Treating Patients with Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and under
Trial IDs: 2012-0999, NCI-2014-01982, NCT02083250
Bortezomib and Clofarabine in Treating Patients with Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0161, NCI-2014-00816, 140161, 141572, 344856, NCI-2014-01108, 9762, NCT02211755
Clofarabine, Cyclophosphamide, and Etoposide in Treating Patients With Acute Leukemia
Phase: No phase specified
Type: Treatment
Age: 60 and under
Trial IDs: HM2012-05, NCI-2013-00966, 1304M30981, 2011LS158, NCT01677949
Start Over